The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 16 March 2004, www.theannals.com, DOI 10.1345/aph.1D462.
 The Annals of Pharmacotherapy: Vol. 38, No. 5, pp. 874-881. DOI 10.1345/aph.1D462
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swegle, J. M
Right arrow Articles by Kelly, M. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swegle, J. M
Right arrow Articles by Kelly, M. W

NEW DRUG DEVELOPMENT

Tibolone: A Unique Version of Hormone Replacement Therapy

John M Swegle, PharmD

Assistant Professor (Clinical), College of Pharmacy, The University of Iowa, Mercy Family Medicine Residency Program, Mason City, IA

Michael W Kelly, PharmD MS

Associate Professor (Clinical), Department of Family Medicine, College of Pharmacy, The University of Iowa, Iowa City, IA

Reprints: John M Swegle PharmD, College of Pharmacy, The University of Iowa, Mercy Family Medicine Residency Program, 1000 4th Street SW, Mason City, IA 50401-2859, fax 641/422-7125, john-swegle{at}uiowa.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of tibolone in the treatment of menopausal symptoms and the prevention of osteoporosis.

DATA SOURCES: Information was obtained from a MEDLINE search (1966–July 2003) and from Organon International. The bibliographies of reviewed literature were searched for additional studies.

STUDY SELECTION AND DATA EXTRACTION: Studies and review articles evaluating tibolone were evaluated. Since tibolone has been available for many years in Europe and has an extensive literature base, this review emphasizes information from studies published after 1995.

DATA SYNTHESIS: Tibolone possesses estrogenic activity and is effective for treating the symptoms and osteoporosis associated with menopause. While the impact of tibolone on the risk of breast cancer or cardiovascular and thromboembolic events is not well defined, its unique pharmacologic profile may provide a safer alternative to traditional hormone replacement therapy. Although widely used for many years in other countries, tibolone has not been approved for use in the US.

CONCLUSIONS: Results of recent trials have led to questions regarding the safety of established hormone replacement therapies in peri- and postmenopausal women. Tibolone appears to be an attractive alternative to these traditional regimens. Additional studies will determine whether the promise of increased safety with tibolone will be realized.

Key Words: hormone replacement therapy, menopause, tibolone

Published Online, March 16, 2004. www.theannals.com, DOI 10.1345/aph.1D462




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.